Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CAO Barbara Gayle Duncan sold 147 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $163.20, for a total value of $23,990.40. Following the completion of the sale, the chief accounting officer now directly owns 30,661 shares of the company’s stock, valued at $5,003,875.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded up 0.51% during mid-day trading on Wednesday, reaching $153.79. The company’s stock had a trading volume of 546,939 shares. The company’s market capitalization is $3.80 billion. The firm’s 50 day moving average is $158.36 and its 200-day moving average is $150.43. Intercept Pharmaceuticals Inc. has a 52-week low of $89.76 and a 52-week high of $217.99.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.69) by $0.55. The business earned $5.52 million during the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The company’s revenue was up 1140.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.99) earnings per share. Analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current year.
Several research firms have recently weighed in on ICPT. Wedbush reissued a “buy” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a report on Saturday, July 9th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $200.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Laidlaw downgraded Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and decreased their price target for the stock from $345.00 to $105.00 in a report on Friday, August 5th. BMO Capital Markets reaffirmed an “outperform” rating and set a $218.00 price target (down from $219.00) on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Five analysts have rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $177.67.
Several hedge funds have recently made changes to their positions in the stock. Context Capital Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at $2,650,000. JPMorgan Chase & Co. raised its stake in shares of Intercept Pharmaceuticals by 198.2% in the second quarter. JPMorgan Chase & Co. now owns 829,438 shares of the biopharmaceutical company’s stock valued at $118,345,000 after buying an additional 551,324 shares during the period. Carmignac Gestion raised its stake in shares of Intercept Pharmaceuticals by 19.6% in the second quarter. Carmignac Gestion now owns 1,993,592 shares of the biopharmaceutical company’s stock valued at $284,446,000 after buying an additional 326,855 shares during the period. Capital World Investors raised its stake in shares of Intercept Pharmaceuticals by 8.4% in the second quarter. Capital World Investors now owns 2,053,959 shares of the biopharmaceutical company’s stock valued at $293,059,000 after buying an additional 160,000 shares during the period. Finally, Altrinsic Global Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 65.5% in the first quarter. Altrinsic Global Advisors LLC now owns 292,687 shares of the biopharmaceutical company’s stock valued at $37,601,000 after buying an additional 115,870 shares during the period. Institutional investors and hedge funds own 81.86% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.